As scientists learn more about the underlying causes of multiple sclerosis (MS), they are developing intelligent interventions that slow or halt the progression of the disease.

In this Front Row lecture, Scripps Research Professor Hugh Rosen will share how he and his collaborators at Scripps Research created ozanimod (Zeposia), the first disease-altering MS therapy, recently approved in the United States and Europe.

Luke Lairson, an associate professor at Scripps Research, will discuss how his research targeting another aspect of the disease is laying the groundwork for the next generation of MS therapies.